PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT
MEMORANDUM
TO: Alan Ngo, Responsible Partner, IP Litigation, Calderwood & Harkness LLP
FROM: Wendy Schultz, Lead Associate, IP Litigation; Omar Siddiqui, Working Associate, IP Litigation
DATE: April 8, 2024
RE: Analysis of Permanent Injunction Under Northgate Group v. MercExchange, L.L.C., 547 U.S. 388 (2006) — Optiwave Semiconductor Corp. v. Lumicore Technologies, Inc., Case No. 2:24-cv-00319-JRG (E.D. Tex.)
CLIENT: Optiwave Semiconductor Corp. ("OWS")
MATTER NO.: 1014-00004
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to assess the entitlement of our client, Optiwave Semiconductor Corp. ("OWS"), to a permanent injunction against Lumicore Technologies, Inc. ("Lumicore") under the four-factor framework established by the Supreme Court in Northgate Group v. MercExchange, L.L.C., 547 U.S. 388 (2006), following what we anticipate will be a favorable outcome on the merits at trial. This analysis is intended to guide trial preparation, discovery strategy, and the development of the evidentiary record necessary to support a post-trial motion for permanent injunctive relief.
Overall Conclusion. Based on our analysis of the operative facts, the applicable legal standards, and the body of post-Cascade Holdings precedent from the Federal Circuit and the Eastern District of Texas, we conclude that OWS has a strong case for a permanent injunction on all four Cascade Holdings factors. OWS is a practicing entity that directly competes with Lumicore in the silicon-photonics transceiver market for hyperscale data centers. OWS suffers ongoing, irreparable competitive harm — including market-share erosion, price erosion, loss of critical design-in opportunities, and degradation of customer relationships — that monetary damages alone cannot fully remedy. The balance of hardships tips decidedly in OWS's favor, particularly in light of Lumicore's knowing assumption of the risk of continued infringement, and the public interest in maintaining the integrity of the patent system supports the issuance of an injunction.
The underlying complaint was filed on April 22, 2024, in the United States District Court for the Eastern District of Texas, marshall Division, before the Honorable James R. Gilstrap (Senior District Judge). The action asserts four utility patents owned by OWS:
• U.S. Patent No. 10,234,847 (the "'847 Patent")
• U.S. Patent No. 10,891,193 (the "'193 Patent")
• U.S. Patent No. 9,678,562 (the "'562 Patent")
• U.S. Patent No. 11,402,015 (the "'015 Patent")
The accused products are Lumicore's LumiLink 400G-ZR+, LumiLink 800G-DR8, and LumiEdge 1600G-LR transceiver modules. The permanent injunction sought would bar Lumicore, its officers, agents, servants, employees, attorneys, subsidiaries, affiliates, and all persons in active concert or participation with them from making, using, selling, offering to sell, or importing the accused products and any colorable imitations thereof within the United States.
Recommendation. We recommend that OWS seek a permanent injunction as part of its post-trial relief following a favorable jury verdict on infringement. Consistent with client instruction, we do not recommend pursuing a preliminary injunction at this time absent a triggering event, such as the launch of a new accused product by Lumicore or a major customer win by Lumicore that would significantly accelerate the competitive injury to OWS. A separate contingency analysis for a preliminary injunction motion is being prepared in draft form should circumstances change.
The balance of this memorandum provides a detailed analysis of each of the four Cascade Holdings factors as applied to the facts of this case, identifies potential counterarguments and our recommended responses, proposes the scope of the injunction to be sought, and sets forth strategic recommendations for developing the evidentiary record during discovery and presenting the injunction case at trial.
II. Background
A. The Parties
1. Optiwave Semiconductor Corp. ("OWS")
Optiwave Semiconductor Corp. is a Delaware corporation headquartered at 4810 Bayside Technology Parkway, Suite 300, Santa Clara, California 95054. Founded in 2011 by Dr. Priya Ramaswamy and Dr. Jian-Wei Huang, OWS is a fabless semiconductor company specializing in the design and commercialization of silicon photonics chipsets for data-center interconnects. The company has grown steadily over the past thirteen years and currently employs approximately 1,250 people across its Santa Clara headquarters, a design center in Portland, Oregon, and field offices in Dallas, Texas, and Raleigh, North Carolina.
OWS is the third-largest U.S. supplier of silicon-photonics transceiver modules for hyperscale data centers, a position it has earned through sustained investment in research and development and aggressive commercialization of its proprietary technologies. For fiscal year 2023, OWS reported total revenue of $487.3 million and net income of $61.4 million. The company holds 142 issued U.S. patents and has 58 additional patent applications pending before the United States Patent and Trademark Office ("USPTO"), spanning technologies in silicon-photonic waveguide design, coherent transceiver integration, thermal management of photonic integrated circuits, and advanced grating coupler architectures.
OWS's key product lines include the OWS-400ZR, OWS-800XR, and OWS-1600DR transceiver module families, which are the products at the center of the competitive overlap with Lumicore's accused products. These product families are sold to hyperscale data-center operators, cloud service providers, and telecommunications companies worldwide.
The company's executive leadership team consists of:
• Chief Executive Officer: Dr. Priya Ramaswamy
• Chief Technology Officer: Dr. Jian-Wei Huang
• General Counsel: Rebecca Tanaka
• VP Engineering, Photonics Division: Dr. Nikolai Petrov
• Chief Financial Officer: David Leitner
OWS's majority owner is Ridgeline Capital Partners, LP, a San Francisco-based private equity firm that acquired a 55% equity stake in OWS in 2019 for approximately $780 million. Ridgeline's investment thesis was predicated in significant part on the value of OWS's intellectual property portfolio and the company's competitive position in the rapidly growing silicon-photonics market. The Board of Directors is chaired by Franklin Osei, a Ridgeline Capital designee. OWS's independent auditor is Gresham & Whitfield LLP.
2. Lumicore Technologies, Inc. ("Lumicore")
Lumicore Technologies, Inc. is a Delaware corporation headquartered at 9200 Spectrum Boulevard, Building C, Austin, Texas 78759. Founded in 2015, Lumicore is a fast-growing entrant in the silicon-photonics transceiver market, targeting both hyperscale data-center and telecommunications applications. The company currently employs approximately 870 people and has expanded rapidly in recent years, driven in large part by the commercial success of the accused product lines at issue in this litigation.
Lumicore's estimated fiscal year 2023 revenue was approximately $312.6 million. The company completed an initial public offering on the Nasdaq Global Select Market in March 2022 at an offering price of $24.00 per share. As of the filing of the complaint, Lumicore's shares were trading at approximately $37.00 per share, giving the company an approximate market capitalization of $3.4 billion based on 91.8 million shares outstanding. Lumicore is thus a well-capitalized public company with access to public capital markets and the resources to fund product redesigns and other operational adjustments.
Lumicore's executive leadership team consists of:
• Chief Executive Officer: Thomas "Tom" Kessler
• Chief Technology Officer: Dr. Sandra Michaud
• General Counsel: Raymond Bautista
• VP Product Development: Dr. Eric Dalmqvist
• Chief Financial Officer: Janet Moreno
Lumicore's independent auditor is Brennan Kellogg & Associates LLP. In this litigation, Lumicore is represented by Hawthorne Vega & Cruz LLP, with lead partner Catherine "Kate" Rourke heading the defense team.
B. The Asserted Patents and Accused Products
1. The Asserted Patents
OWS asserts four utility patents in this action, each directed to a distinct aspect of silicon-photonic transceiver technology:
The '847 Patent (U.S. Patent No. 10,234,847), entitled "Multi-Channel Silicon Photonic Waveguide Multiplexer with Low Insertion Loss," was filed on September 14, 2016, and issued on March 19, 2019. The original assignee is OWS. The '847 Patent claims a novel waveguide multiplexer architecture that achieves significantly lower insertion loss than prior art designs, enabling higher-bandwidth, more energy-efficient optical communications in data-center environments. The named inventors are Dr. Jian-Wei Huang and Dr. Nikolai Petrov.
The '193 Patent (U.S. Patent No. 10,891,193), entitled "High-Bandwidth Coherent Optical Transceiver Integrated on Silicon Substrate," was filed on April 7, 2017, and issued on January 12, 2021. The original assignee is OWS. The '193 Patent claims a coherent optical transceiver architecture integrated on a silicon substrate that enables high-bandwidth data transmission with reduced power consumption and footprint relative to discrete-component designs. The named inventors include Dr. Jian-Wei Huang, Dr. Nikolai Petrov, and Dr. Maria Vasquez (formerly a Senior Staff Engineer at OWS).
The '562 Patent (U.S. Patent No. 9,678,562), entitled "Method for Thermal Management of Photonic Integrated Circuits Using Embedded Micro-Channel Heat Sinks," was filed on November 22, 2014, and issued on June 13, 2017. The original assignee was Solara Optics, Inc., a company that specialized in advanced thermal management solutions for photonic and optoelectronic devices. OWS acquired the '562 Patent, along with eleven other patents from the Solara Optics portfolio, pursuant to an Asset Purchase Agreement dated June 15, 2018, for a total consideration of $34.5 million. The '562 Patent claims a method for embedding micro-channel heat sinks within photonic integrated circuits to manage thermal loads, a technology critical to the reliable operation of high-power silicon-photonic transceivers.
The '015 Patent (U.S. Patent No. 11,402,015), entitled "Polarization-Diverse Grating Coupler for Silicon Photonic Transceivers," was filed on August 30, 2019, and issued on August 2, 2022. The original assignee is OWS. The '015 Patent claims a polarization-diverse grating coupler design that improves coupling efficiency between optical fibers and silicon-photonic waveguides, enabling higher data rates and lower bit-error rates in transceiver modules.
The '562 Patent and the '847 Patent share a continuation relationship and belong to the same patent family. The '193 Patent and the '015 Patent share a common provisional application, U.S. Provisional Application No. 62/499,117, filed on April 7, 2017. Together, these four patents cover core enabling technologies for modern silicon-photonic transceiver modules: waveguide multiplexing, coherent transceiver integration on silicon, thermal management, and polarization-diverse optical coupling.
2. The Accused Products
OWS accuses three Lumicore transceiver module product lines of infringement:
The total projected accused-product revenue from Lumicore's initial launch of the LumiLink 400G-ZR+ in Q3 2022 through the anticipated trial date in Q4 2025 is approximately $714.6 million. Notably, the accused product lines constitute a very substantial share of Lumicore's total revenue — approximately 85% of Lumicore's estimated FY 2023 revenue of $312.6 million was generated by the three accused product families.
The LumiLink 400G-ZR+ is Lumicore's flagship 400-gigabit coherent transceiver module, designed for data-center interconnect ("DCI") and long-haul applications. The LumiLink 800G-DR8 is Lumicore's next-generation 800-gigabit transceiver for intra-data-center connectivity, which has achieved rapid customer adoption since its Q1 2023 launch. The LumiEdge 1600G-LR is Lumicore's most recently launched product, a 1600-gigabit long-reach transceiver module that was introduced in Q4 2023 — notably, after Lumicore had received full notice of OWS's patent rights and had declined to take a license.
C. OWS's Competing Products
OWS practices the asserted patents through its own product lines, which directly compete with Lumicore's accused products in the silicon-photonics transceiver market for hyperscale data centers. OWS's competing product families are the OWS-400ZR (competing with the LumiLink 400G-ZR+), the OWS-800XR (competing with the LumiLink 800G-DR8), and the OWS-1600DR (competing with the LumiEdge 1600G-LR).
OWS's gross margin on these competing transceiver products is 47.3%, reflecting the high value of the patented technologies incorporated into these modules. Of OWS's total FY 2023 revenue of $487.3 million, approximately $310 million — roughly 63.6% — is directly attributable to products that practice one or more of the asserted patents. This underscores the centrality of the patented technologies to OWS's business and the competitive significance of the harm caused by Lumicore's infringement.
Critically, OWS and Lumicore compete head-to-head at no fewer than 12 of the top 20 hyperscale data-center operators worldwide. These customers include the largest cloud service providers and internet companies, whose procurement decisions drive the silicon-photonics transceiver market. The degree of competitive overlap between OWS and Lumicore is significant and directly relevant to the irreparable-harm and balance-of-hardships analyses set forth below.
D. Pre-Suit Licensing History
Before initiating this litigation, OWS made substantial efforts to resolve the dispute through pre-suit licensing negotiations. These efforts were conducted through OWS's licensing agent, FairPoint Licensing Group, LLC, under the direction of Managing Director Angela Reeves, in coordination with OWS's General Counsel, Rebecca Tanaka.
The timeline of the pre-suit licensing outreach is as follows:
January 15, 2023: FairPoint Licensing Group, on behalf of OWS, sent an initial licensing and notice letter to Lumicore's General Counsel, Raymond Bautista, identifying the '847, '193, and '562 Patents and providing claim charts mapping Lumicore's LumiLink 400G-ZR+ product to specific claims of those patents. The letter invited Lumicore to enter into licensing negotiations.
February 28, 2023: Lumicore responded through its outside counsel at Hawthorne Vega & Cruz LLP, disputing infringement of the identified patents and questioning the validity of certain claims. The response did not include any substantive technical analysis but indicated that Lumicore was "evaluating its options."
April 20, 2023: An in-person licensing meeting was held in Austin, Texas, attended by Angela Reeves (FairPoint), Rebecca Tanaka (OWS General Counsel), Raymond Bautista (Lumicore General Counsel), and Kate Rourke (lead partner, Hawthorne Vega & Cruz LLP). The meeting lasted approximately three hours. OWS presented its infringement analysis in detail, including updated claim charts for the '847, '193, and '562 Patents as applied to both the LumiLink 400G-ZR+ and the recently launched LumiLink 800G-DR8. Lumicore's representatives took the matter under advisement but did not make any licensing offer or counterproposal. No resolution was reached.
May 15, 2023: FairPoint sent a follow-up licensing letter expanding the scope of the licensing demand to include the '015 Patent (which had issued on August 2, 2022) and adding the LumiLink 800G-DR8 to the list of accused products. The letter reiterated OWS's willingness to negotiate a license on reasonable terms and warned that litigation would be pursued if a resolution could not be reached.
July 10, 2023: Lumicore sent a letter through Hawthorne Vega & Cruz LLP formally declining to take a license, citing "competent legal opinions" regarding non-infringement and invalidity of the asserted patents. The letter did not provide copies of, or substantive details regarding, the referenced legal opinions.
It is significant that Lumicore launched the LumiEdge 1600G-LR in Q4 2023 — approximately three months after formally declining OWS's license offer and with full knowledge and awareness of OWS's patent rights. This fact is relevant to both the willfulness determination and the balance-of-hardships analysis under the Cascade Holdings framework.
III. Legal Framework: The *Cascade Holdings* Four-Factor Test
In Northgate Group v. MercExchange, L.L.C., 547 U.S. 388 (2006), the Supreme Court held that the traditional four-factor test for permanent injunctive relief applies in patent cases, just as it does in other areas of equity. The Court rejected the Federal Circuit's prior rule that a permanent injunction should issue as a matter of course following a finding of patent infringement. Writing for a unanimous Court, Justice Thomas explained that "the decision whether to grant or deny injunctive relief rests within the equitable discretion of the district courts, and that such discretion must be exercised consistent with traditional principles of equity, in patent disputes no less than in other cases governed by such standards." Id. at 394.
Under the Cascade Holdings framework, a plaintiff seeking a permanent injunction must demonstrate:
1. That it has suffered an irreparable injury;
2. That remedies available at law, such as monetary damages, are inadequate to compensate for that injury;
3. That, considering the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and
4. That the public interest would not be disserved by a permanent injunction.
Id. at 391. Each factor must be analyzed on its own facts; the Court emphasized that courts should not adopt "categorical" rules that either always grant or always deny injunctive relief upon a finding of infringement. Id. at 393–94.
In the years since Cascade Holdings, the Federal Circuit and district courts have developed a substantial body of precedent applying these four factors to patent disputes across a wide range of industries and competitive circumstances. Several principles have emerged that are directly relevant to OWS's case.
First, courts have consistently recognized that direct competition between the patentee and the infringer is a strong indicator of irreparable harm and the inadequacy of monetary damages. In Robert Bosch LLC v. Pylon Manufacturing Corp., 659 F.3d 1142, 1150–51 (Fed. Cir. 2011), the Federal Circuit held that where a patentee and an infringer are direct competitors, the patentee's "loss of market share, lost downstream sales, and lost business opportunities" constitute irreparable harm. The court explained that "[w]hen the patentee and the infringer are competitors, the injury suffered by the patentee because of the infringement—in the form of lost sales, price erosion, and loss of customer goodwill—is often difficult, if not impossible, to quantify." Id. at 1152.
Second, in Camberwell & Co. v. Quillon Corporation, 809 F.3d 633, 641–44 (Fed. Cir. 2015), the Federal Circuit clarified that a patentee seeking injunctive relief must establish a causal nexus between the alleged harm and the infringement — that is, the patentee must show that the infringing features, rather than other product attributes, drive consumer demand for the accused products. While the Tidewater Industries nexus requirement applies primarily in complex-product cases where the patented feature is one of many components, the requirement is substantially easier to satisfy where the patented technologies are core to the accused products' functionality, as is the case here.
Third, decisions from the Eastern District of Texas are particularly instructive given that this action is pending before Judge Gilstrap in the marshall Division. In Genband US LLC v. Metaswitch Networks Corp., No. 2:14-cv-33-JRG (E.D. Tex.), Judge Gilstrap granted a permanent injunction to a practicing-entity patentee that directly competed with the infringer, crediting evidence of lost sales, competitive overlap, and the ongoing nature of the harm. Other E.D. Tex. judges have similarly granted permanent injunctions in cases involving competing commercial products, recognizing that the equities strongly favor injunctive relief where the patentee is not merely seeking to monetize patents but is actively commercializing the patented technology in a competitive market.
It is also important to emphasize that courts in the Eastern District of Texas and elsewhere have regularly distinguished cases involving practicing entities and direct competitors — where permanent injunctions are commonly granted — from cases involving non-practicing entities ("NPEs") or patent assertion entities ("PAEs"), where injunctions are more frequently denied. The reasoning is straightforward: an NPE that does not participate in the market for the patented technology typically does not suffer irreparable competitive harm from infringement, and monetary damages in the form of a reasonable royalty generally provide an adequate remedy. Here, OWS is the antithesis of an NPE: it is a major market participant that practices the asserted patents through its own product lines and competes directly and vigorously with Lumicore for the same customers in the same market.
With this legal framework in mind, we turn to the application of each Cascade Holdings factor to the facts of OWS's case.
IV. Factor 1: Irreparable Harm
The first and most significant Cascade Holdings factor asks whether OWS has suffered — and continues to suffer — irreparable injury as a result of Lumicore's infringement. Our analysis demonstrates that OWS has a strong showing of irreparable harm across multiple, interrelated dimensions: direct competition and market-share erosion, price erosion, loss of customer relationships and design-in opportunities, and harm to innovation incentives and goodwill.
A. Direct Competition and Market-Share Erosion
OWS and Lumicore are direct competitors in the silicon-photonics transceiver market for hyperscale data centers. This is not a case where the patentee and the infringer operate in different market segments or where the accused products serve a different customer base. To the contrary, OWS is the third-largest U.S. supplier of silicon-photonics transceiver modules, and Lumicore is the fastest-growing entrant into the same market. The two companies compete head-to-head for the business of the largest and most important customers in the industry — at least 12 of the top 20 hyperscale data-center operators worldwide purchase transceiver products from both OWS and Lumicore.
The accused products are direct substitutes for OWS's competing product lines. Lumicore's LumiLink 400G-ZR+ competes directly with OWS's OWS-400ZR module; Lumicore's LumiLink 800G-DR8 competes directly with OWS's OWS-800XR module; and Lumicore's LumiEdge 1600G-LR competes directly with OWS's OWS-1600DR module. In each case, the products serve the same function — enabling high-bandwidth optical data transmission within and between data centers — and are evaluated by the same customers using substantially the same performance criteria, including data rate, power consumption, insertion loss, thermal performance, and form factor.
OWS's preliminary analysis, supported by market-share displacement data assembled by its competitive intelligence team and verified by our damages consultants, demonstrates that Lumicore's accused products have displaced approximately 38.2% of what would have been OWS's sales in the overlapping customer accounts. This displacement is ongoing and accelerating as Lumicore's product lines mature and gain broader market acceptance.
The significance of market-share erosion in the semiconductor and optical-networking industries cannot be overstated. Unlike consumer goods markets where lost sales can potentially be recaptured in subsequent periods, the silicon-photonics transceiver market is characterized by customer "design-in" decisions that create long-term lock-in effects. When a hyperscale data-center operator qualifies a particular transceiver module for use in its data-center architecture, that decision has ramifications extending over multiple product generations. The customer invests significant engineering resources in qualifying the product, integrating it into its network management systems, developing compatible firmware, and training its operations staff. Once this investment has been made, the switching costs are substantial, and the vendor relationship typically persists for three to five years — the full lifecycle of the data-center platform generation.
As a result, each sale that Lumicore makes of an accused product does not merely represent a single lost transaction for OWS; it represents the loss of a long-term customer relationship and a multi-year revenue stream. The cascading effects of these design-in losses are inherently difficult to reverse, even if Lumicore ultimately exits the market or redesigns its products. Customers that have already committed to Lumicore's architecture are unlikely to incur the cost and disruption of switching back to OWS's products, even if those products are technologically superior.
B. Price Erosion
In addition to market-share erosion, OWS has suffered significant price erosion as a direct result of Lumicore's entry into the market with infringing products. The average selling prices ("ASPs") of 400G-ZR transceivers across the market declined approximately 18.7% from Q3 2022, when Lumicore launched the LumiLink 400G-ZR+, through Q4 2023. While some degree of ASP decline is expected over time in the semiconductor industry as manufacturing yields improve and competition intensifies, OWS's internal pricing analysis and discussions with its sales team indicate that a substantial portion of the accelerated price decline is attributable to Lumicore's aggressive pricing of its infringing products.
Lumicore's strategy of undercutting OWS's pricing has forced OWS to reduce its own prices to remain competitive for customer engagements. This price erosion affects not only the specific transceiver SKUs that compete directly with Lumicore's accused products, but also adjacent product lines and configurations, as customers use Lumicore's lower pricing as leverage in negotiations across their entire transceiver procurement portfolios.
The price erosion caused by Lumicore's infringement is particularly harmful because it is extremely difficult to reverse. Once prices in the transceiver market have been driven down, it is nearly impossible for any single supplier to raise prices back to pre-competition levels, even if the infringing competitor is ultimately removed from the market. The irreversible nature of this price erosion supports OWS's claim of irreparable harm and underscores the inadequacy of monetary damages to make OWS whole.
Moreover, as discussed further in Section V below, price erosion damages are inherently difficult to quantify with precision. The ASP decline is attributable to a complex mix of factors, including competitive pressure from Lumicore, market maturation, improvements in manufacturing technology, and macroeconomic conditions. Disentangling the portion attributable specifically to Lumicore's infringement — as opposed to these other factors — requires economic modeling that inevitably involves significant uncertainty. This inherent difficulty in quantification is itself evidence that legal remedies are inadequate.
C. Loss of Customer Relationships and Design-In Opportunities
Beyond aggregate market-share and pricing data, OWS has suffered the loss of specific, identifiable customer relationships and design-in opportunities as a direct result of Lumicore's infringing products. These losses will be documented at trial through declarations and testimony from OWS's VP of Sales, Karen Whitfield, and regional sales directors who have firsthand knowledge of specific competitive engagements in which OWS lost business to Lumicore's accused products.
The transceiver market operates on a design-in model in which a customer's selection of a particular transceiver module for use in its data-center architecture is the critical commercial event. Being "designed in" to a customer's architecture leads to follow-on purchases over a three-to-five-year product lifecycle, as the customer deploys the transceiver module across its data-center fleet. The initial design-in win is thus the gateway to a sustained revenue stream that can amount to tens or even hundreds of millions of dollars over the product cycle, depending on the scale of the customer's operations.
When OWS loses a design-in opportunity to Lumicore's infringing product, it loses not just the initial order but the entire downstream revenue stream associated with that customer platform generation. And because of the switching costs and lock-in effects described above, the lost design-in opportunity is extremely difficult — and often impossible — to recapture. Even if Lumicore's products were to be enjoined and removed from the market at a future date, the customer would likely seek an alternative supplier or delay procurement rather than return to OWS, particularly if the customer has already made significant investment in qualifying Lumicore's product and integrating it into its systems.
This dynamic is well recognized in the semiconductor industry and has been credited by courts as a basis for finding irreparable harm in patent cases involving competing semiconductor and electronics products. The lost design-in opportunities represent a form of competitive injury that is particularly ill-suited to compensation through monetary damages, because the full scope of the loss — including follow-on sales, customer goodwill, and competitive positioning over multiple product generations — is inherently speculative and cannot be captured in a backward-looking damages model.
D. Harm to Innovation Incentives and Goodwill
OWS has invested heavily in research and development over the thirteen years since its founding, building a patent portfolio of 142 issued U.S. patents and 58 pending applications. The four asserted patents represent core technologies in silicon-photonic waveguide design, coherent transceiver integration, thermal management, and polarization-diverse optical coupling — technologies that are the product of years of sustained R&D investment by OWS's engineering team under the leadership of Dr. Jian-Wei Huang (CTO) and Dr. Nikolai Petrov (VP Engineering, Photonics Division).
If Lumicore is permitted to continue practicing OWS's patented inventions without injunctive relief — even upon payment of court-awarded damages — the practical effect is to convert OWS's exclusive patent rights into a compulsory license. This outcome would fundamentally undermine OWS's incentives to continue investing in innovation. If competitors know that infringement of OWS's patents will result in nothing more than a monetary payment — a cost of doing business — they will have reduced incentive to develop their own non-infringing technologies and increased incentive to simply copy OWS's inventions. Over time, this dynamic would erode the competitive advantage that OWS derives from its patent portfolio and diminish the return on its R&D investment.
The concern is not merely theoretical. OWS's majority owner, Ridgeline Capital Partners, LP, acquired its 55% stake in OWS in 2019 for approximately $780 million. A central element of Ridgeline's investment thesis was the value and defensibility of OWS's intellectual property portfolio. Ongoing infringement by a major competitor — particularly without the ability to obtain injunctive relief — diminishes the value of the IP portfolio and, by extension, the value of Ridgeline's investment. This has implications not only for OWS's current capitalization but also for its ability to attract future investment and maintain its competitive position in a rapidly evolving market.
Additionally, OWS suffers reputational harm that is difficult to quantify in monetary terms. OWS's reputation as an innovator and technology leader in the silicon-photonics market is a critical intangible asset. When a competitor is able to bring to market products that embody OWS's patented technologies without consequence, it undermines OWS's reputation as a differentiated supplier and erodes the premium that customers are willing to pay for OWS's products.
E. Post-*Cascade Holdings* Case Law Supporting Irreparable Harm for Direct Competitors
The foregoing analysis is strongly supported by post-Cascade Holdings case law from the Federal Circuit and the Eastern District of Texas. In Robert Bosch LLC v. Pylon Manufacturing Corp., 659 F.3d 1142, 1150–52 (Fed. Cir. 2011), the Federal Circuit held that direct competition between the patentee and the infringer creates a strong basis for finding irreparable harm, because the patentee's loss of market share, lost downstream sales, and lost business opportunities are "often difficult, if not impossible, to quantify." The court emphasized that "[t]he fact that Bosch competes directly with Pylon strongly supports a finding that Bosch would be irreparably harmed by Pylon's continued infringement."
Similarly, in Presidio Components, Inc. v. American Technical Ceramics Corp., 702 F.3d 1351, 1362–63 (Fed. Cir. 2012), the Federal Circuit affirmed a permanent injunction where the patentee was a practicing entity in direct competition with the infringer, finding that the patentee had established irreparable harm through evidence of lost market share, price erosion, and the ongoing nature of the competitive injury. The court credited testimony regarding the difficulty of recapturing lost customers and the long-term effects of competitive displacement.
In the Eastern District of Texas, judges have consistently granted permanent injunctions to practicing-entity patentees that compete directly with the infringer. See, e.g., Genband US LLC v. Metaswitch Networks Corp., No. 2:14-cv-33-JRG (E.D. Tex.) (Judge Gilstrap granting permanent injunction to competing software company); Commonwealth Scientific & Industrial Research Organisation v. Sterling Reach Holdings, No. 6:11-cv-343-LED (E.D. Tex.) (permanent injunction granted to patentee competing in wireless technology market). These decisions recognize that the equities strongly favor injunctive relief where the patentee is not merely seeking to extract a royalty but is actively commercializing its patented technology in competition with the infringer.
By contrast, cases in which permanent injunctions have been denied under Cascade Holdings typically involve factual circumstances that are fundamentally distinguishable from OWS's case. Injunctions have been denied where the patentee is a non-practicing entity that does not participate in the relevant market, see, e.g., z4 Technologies, Inc. v. Kestrel Partners LLC, 434 F. Supp. 2d 437, 440–41 (E.D. Tex. 2006); where the patented feature represents only a small component of a complex product and the patentee does not compete in the market for that product, see Tidewater Industries, 809 F.3d at 643–44; or where the patentee has engaged in a pattern of licensing its patents rather than practicing them, suggesting that a reasonable royalty is an adequate remedy, see Cascade Holdings, 547 U.S. at 396 (Kennedy, J., concurring). None of these distinguishing factors is present here.
V. Factor 2: Inadequacy of Legal Remedies
The second Cascade Holdings factor requires OWS to demonstrate that remedies available at law — principally monetary damages — are inadequate to compensate for the injury caused by Lumicore's infringement. This factor is closely related to the first factor and, as discussed below, is strongly supported by the same evidence.
A. Ongoing Nature of the Harm
Monetary damages, no matter how substantial, cannot fully compensate OWS for the ongoing competitive injury it suffers with each day that Lumicore continues to sell infringing products. OWS's damages demand of approximately $210 million is intended to address the harm that Lumicore's infringement has already caused through the date of trial. But a damages award — even a large one — is inherently backward-looking. It compensates OWS for past harm but does nothing to prevent the continuation of that harm into the future.
Each new sale by Lumicore of an accused transceiver module potentially represents a lost design-in opportunity for OWS. As discussed in Section IV.C above, a lost design-in opportunity is not a discrete, one-time event; it is the loss of a multi-year revenue stream extending over the full lifecycle of the customer's data-center platform generation. A damages award calculated based on Lumicore's past sales cannot account for the future follow-on sales and customer-relationship value that OWS will lose as a result of design-in decisions that have not yet been made — or that are being made during the pendency of this litigation.
Moreover, the projected trajectory of Lumicore's accused-product sales is sharply upward. Total accused-product revenue is projected to reach approximately $714.6 million through the anticipated trial date in Q4 2025. If Lumicore is not enjoined after trial, the competitive injury to OWS will continue to escalate as Lumicore's products gain broader market acceptance and deeper customer integration.
B. Difficulty in Quantifying Certain Harms
Several categories of harm caused by Lumicore's infringement are inherently difficult — if not impossible — to quantify with the precision required to make OWS whole through a monetary award.
Price erosion across the entire transceiver market is attributable to a complex mix of competitive, technological, and macroeconomic factors. While OWS's economic experts will present their best estimates of the price erosion attributable to Lumicore's infringement, any such estimate necessarily involves significant assumptions and modeling choices. The inherent uncertainty in quantifying price erosion means that any damages award based on price erosion is likely to either overcompensate or undercompensate OWS — and the risk of undercompensation is substantial. This uncertainty itself supports the conclusion that monetary damages are an inadequate remedy.
Loss of goodwill and reputational harm from being undercut by an infringing competitor cannot be reduced to a dollar figure with any meaningful precision. OWS's reputation as a technology leader and innovator in the silicon-photonics market is a function of customer perceptions, industry recognition, and competitive positioning — factors that are inherently qualitative and resistant to monetization.
Erosion of first-mover advantage in the technologies covered by the asserted patents is a non-monetary competitive harm that cannot be remedied through damages. OWS invested in developing these technologies with the expectation that its patent rights would enable it to maintain a competitive advantage in the market. Each day that Lumicore sells infringing products, that first-mover advantage is further eroded — not in a way that can be precisely measured and compensated after the fact, but in a way that permanently alters the competitive landscape.
C. Compulsory License Concern
If the Court declines to issue a permanent injunction following a finding of infringement, the practical effect is to impose a compulsory license on OWS, allowing Lumicore to continue using OWS's patented technology upon payment of an ongoing royalty set by the Court. This outcome is fundamentally at odds with the nature of patent rights and the policies underlying the patent system.
The Patent Act grants patentees "the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States, and, if the invention is a process, of the right to exclude others from using, offering for sale, or selling throughout the United States, or importing into the United States, products made by that process." 35 U.S.C. § 154(a)(1). The right to exclude is the cornerstone of the patent grant. Converting that right into a right to collect a royalty — as a court-imposed compulsory license would do — fundamentally alters the nature of the patent right and undermines the patentee's ability to make independent commercialization and licensing decisions.
In this case, OWS attempted in good faith to license its patents to Lumicore through FairPoint Licensing Group. Those efforts extended over a period of approximately six months, from January through July 2023, and included an in-person licensing meeting in Austin, Texas. Lumicore declined to take a license, citing "competent legal opinions." Having been offered and refused a license, Lumicore chose to take the risk of continued infringement. OWS should not now be forced to accept a court-imposed royalty — on terms that it did not negotiate and does not control — as a substitute for the injunctive relief to which it is entitled.
The concerns raised by the Cascade Holdings concurrences further support this analysis. Chief Justice Roberts, joined by Justices Scalia and Ginsburg, noted that "from at least the early 19th century, courts have granted injunctive relief upon a finding of infringement in the vast majority of patent cases," and that "[t]his long tradition of equity practice is not surprising, given the difficulty of protecting a right to exclude through monetary remedies." Cascade Holdings, 547 U.S. at 395 (Roberts, C.J., concurring). Justice Kennedy, joined by Justices Stevens, Souter, and Breyer, observed that the compulsory-license concern is most acute where "the patentee practices its inventions" and the infringer is a direct competitor, as opposed to cases involving non-practicing entities seeking to extract licensing fees. Id. at 396 (Kennedy, J., concurring).
D. Multiple Damages Theories Reflect Complexity, Not Adequacy
OWS anticipates presenting multiple damages theories at trial: lost profits of approximately $128.9 million on sales displaced by Lumicore's infringement; a reasonable royalty of approximately $37.5 million (at a rate of 8.5%) on non-displaced sales; and a claim for enhanced damages based on Lumicore's willful infringement. The total damages demand is approximately $210 million.
Lumicore may argue that the magnitude of OWS's damages demand demonstrates that monetary remedies are adequate. This argument should be rejected. The fact that OWS pursues multiple damages theories does not mean that any or all of them are sufficient to make OWS whole. To the contrary, the need for multiple, alternative damages theories reflects the inherent complexity and difficulty of capturing the full scope of harm caused by Lumicore's infringement in any single monetary model.
Lost profits, for example, compensate OWS only for sales that can be demonstrated with reasonable probability to have been diverted from OWS to Lumicore. They do not capture the long-tail effects of lost design-in opportunities, the future revenue streams associated with follow-on purchases, or the price erosion that affects OWS's entire product portfolio. The reasonable royalty component addresses non-displaced sales — sales that Lumicore made that OWS would not have captured — but represents only a fraction of the value of the patented technology. And enhanced damages for willfulness, while punitive in character, do not compensate OWS for the ongoing future harm that will continue if Lumicore is not enjoined.
In sum, the multiple damages theories reflect the multifaceted nature of the harm caused by Lumicore's infringement — harm that, in its totality, cannot be fully addressed by any backward-looking monetary award.
VI. Factor 3: Balance of Hardships
The third Cascade Holdings factor requires the Court to consider the balance of hardships between the parties in determining whether equitable relief is warranted. As analyzed below, the balance tips decidedly in favor of OWS.
A. Hardship to OWS Absent an Injunction
The hardship to OWS if the Court declines to issue a permanent injunction is severe and ongoing. Every day that Lumicore continues to sell infringing products, OWS loses additional market share, forfeits additional design-in opportunities, and suffers further erosion of its pricing power. These competitive injuries are cumulative and, to a significant degree, irreversible.
OWS's FY 2023 revenue of $487.3 million and its position as the third-largest U.S. silicon-photonics transceiver supplier are at stake. Approximately $310 million of OWS's FY 2023 revenue — 63.6% of total revenue — was generated by products that practice the asserted patents and compete directly with Lumicore's accused products. The ongoing erosion of OWS's competitive position in these product lines threatens the financial viability of a significant portion of OWS's business.
Without an injunction, Lumicore's continued growth — Lumicore's FY 2023 revenue was $312.6 million, with accused products comprising approximately 85% of that total ($264.9 million) — will further entrench Lumicore's position in the market and make it progressively more difficult for OWS to compete. The hyperscale data-center market is characterized by rapid growth and intense competition, and the competitive advantages gained by Lumicore through infringement — including customer relationships, market presence, and brand recognition — compound over time.
Perhaps most fundamentally, OWS has a legitimate right under the Patent Act to exclude competitors from practicing its patented inventions. The denial of an injunction would effectively eviscerate this right, converting it into a mere entitlement to collect a royalty. For a company like OWS, which commercializes its patents through its own products and competes directly with the infringer, the right to exclude is not an abstract concept but a concrete, commercially significant right that is essential to maintaining its competitive position.
B. Hardship to Lumicore if Injunction is Granted
Lumicore will undoubtedly argue that a permanent injunction would impose severe hardship on its business. OWS acknowledges that the injunction would affect a significant portion of Lumicore's product revenue. However, a careful analysis demonstrates that the hardship to Lumicore does not outweigh the hardship to OWS.
OWS's analysis estimates that an injunction would affect approximately 42% of Lumicore's total product revenue, accounting for overlap with non-accused configurations and the potential for redesign avoidance. While the accused product lines constitute approximately 85% of Lumicore's FY 2023 revenue ($264.9 million of $312.6 million), not all units sold within those product families necessarily infringe all asserted claims, and Lumicore may be able to redesign certain configurations to avoid infringement. The 42% figure represents a conservative estimate of the revenue directly at risk from an injunction.
Lumicore has estimated that a redesign to design around the asserted patents would take approximately 18 to 24 months. While this is a significant timeline, it is not an insurmountable obstacle for a well-capitalized public company. Lumicore's market capitalization is approximately $3.4 billion (based on 91.8 million shares outstanding at $37.00 per share as of the filing date), and the company has access to public capital markets through its Nasdaq listing and its investment banking relationship with Silverstone Capital Markets LLC. Lumicore has the financial resources and engineering talent to execute a redesign — indeed, it has a team of approximately 870 employees, including a CTO (Dr. Sandra Michaud) and VP of Product Development (Dr. Eric Dalmqvist) specifically responsible for product design.
Most critically, any hardship that Lumicore suffers from an injunction is largely self-inflicted. Lumicore was placed on notice of OWS's patent rights no later than January 15, 2023, when FairPoint Licensing Group sent its initial licensing letter. Over the following six months, OWS engaged in good-faith efforts to negotiate a license, culminating in an in-person meeting in Austin, Texas. Lumicore not only declined to take a license but launched a new product — the LumiEdge 1600G-LR — in Q4 2023, after receiving full notice and after formally rejecting OWS's licensing offer. Lumicore made a deliberate business decision to continue infringing, relying on unidentified "competent legal opinions" that it apparently believed would shield it from liability.
Having knowingly assumed the risk of continued infringement, Lumicore cannot now credibly claim that an injunction would impose an inequitable hardship. The Federal Circuit has repeatedly recognized that a defendant's knowledge of the plaintiff's patent rights and decision to continue infringing weighs against the defendant in the balance-of-hardships analysis. See, e.g., Robert Bosch, 659 F.3d at 1156 ("[Defendant's] hardship is largely self-inflicted, since it could have attempted to design around [patentee's] patents."); Presidio Components, 702 F.3d at 1363 (finding that defendant's hardship was self-inflicted where defendant had notice of patents and chose to continue infringing).
Furthermore, Lumicore had the opportunity to take a license — which would have allowed it to continue selling the accused products upon payment of a negotiated royalty — and declined. It also had the opportunity to proactively redesign its products to avoid infringement during the period between receiving notice (January 2023) and trial (anticipated Q4 2025), a period of nearly three years. Lumicore's failure to pursue either of these alternatives undermines any claim of disproportionate hardship.
C. Mitigation Provisions — Sunset Period
To address legitimate concerns about existing customer commitments and to ensure an orderly market transition, OWS is prepared to propose a reasonable sunset provision in the injunction order. Specifically, OWS would agree to a sunset period of up to 18 months during which Lumicore would be permitted to fulfill existing, binding customer purchase orders that were entered before the date of the injunction order. During the sunset period, Lumicore would be required to submit periodic reports to OWS (or to a court-appointed monitor) documenting the purchase orders being fulfilled and the quantities shipped, and OWS would have the right to audit these reports.
This approach is consistent with established judicial practice in the Eastern District of Texas and other jurisdictions. Courts routinely include sunset provisions in permanent injunction orders to balance the need for injunctive relief against the practical realities of commercial relationships and supply commitments. See, e.g., Paice LLC v. Northpoint Enterprises Motor Corp., 504 F.3d 1293, 1315 (Fed. Cir. 2007) (discussing the availability of transitional provisions in injunction orders); Westvale Holdings. v. Emulex Corp., 732 F.3d 1325, 1337–38 (Fed. Cir. 2013) (approving sunset provision in permanent injunction).
An 18-month sunset period is appropriate here because it aligns with Lumicore's own estimate of the time required for a redesign (18 to 24 months), giving Lumicore a reasonable runway to transition its customers to non-infringing products while ensuring that OWS's exclusionary rights are ultimately vindicated.
D. Balance Tips in Favor of OWS
In summary, the balance of hardships favors OWS for the following reasons:
(a) OWS suffers continuing, irreparable competitive injury from Lumicore's ongoing infringement, including market-share erosion, price erosion, loss of design-in opportunities, and harm to innovation incentives;
(b) Lumicore knowingly assumed the risk of infringement by continuing to sell accused products — and launching a new accused product — after receiving notice of OWS's patent rights and declining to take a license;
(c) Lumicore is a well-capitalized public company with the financial resources and engineering capability to execute a redesign within a reasonable timeframe; and
(d) A sunset provision of up to 18 months can mitigate any legitimate transition hardship to Lumicore and its existing customers.
Considering these factors in their totality, the balance of hardships weighs decisively in favor of granting a permanent injunction.
VII. Factor 4: Public Interest
The fourth and final Cascade Holdings factor asks whether the public interest would be disserved by a permanent injunction. Our analysis concludes that the public interest affirmatively supports the issuance of a permanent injunction in this case.
A. Patent System Integrity
The public has a strong interest in a robust patent system that incentivizes innovation and rewards those who invest in developing new technologies. This interest is served by granting injunctive relief to a practicing-entity patentee that has demonstrated infringement by a direct competitor. As the Supreme Court recognized in Cascade Holdings, the patent system is designed to promote innovation by granting patentees the right to exclude others from practicing their inventions. When that right is enforced through injunctive relief, the patent system functions as intended — encouraging investment in R&D by ensuring that innovators can capture the returns on their inventions.
Denying a permanent injunction in this case would send a troubling signal to the market: that competitors can freely use patented silicon-photonics technologies so long as they are willing and able to pay damages after the fact. This "pay-to-play" dynamic would undermine the incentive structure of the patent system by converting exclusive patent rights into de facto compulsory licenses. The resulting erosion of innovation incentives would disserve the public interest not only in the silicon-photonics industry but across the broader technology sector.
This concern is particularly acute in the semiconductor and optical-networking industries, where R&D investment is capital-intensive and the lead times for developing new technologies are long. Companies like OWS invest tens of millions of dollars annually in R&D with the expectation that their patent rights will provide a meaningful competitive advantage. If those rights cannot be enforced through injunctive relief, the expected return on R&D investment is diminished, and the incentive to innovate is correspondingly reduced.
B. No Public-Safety or Public-Welfare Concern
The accused products — Lumicore's LumiLink 400G-ZR+, LumiLink 800G-DR8, and LumiEdge 1600G-LR — are commercial transceiver modules used in data-center infrastructure. They are not medical devices, essential medicines, public-safety equipment, or products implicating critical public health or safety functions. Courts have denied permanent injunctions under the public-interest factor in cases where the accused products serve essential public functions — for example, where an injunction would restrict access to life-saving medical devices or essential telecommunications infrastructure. See, e.g., Edwards Lifesciences AG v. CoreValve, Inc., 699 F.3d 1305, 1315–16 (Fed. Cir. 2012) (discussing public-interest concerns in medical-device cases). No such concerns are present here.
Alternative, non-infringing transceiver products are readily available from multiple market participants. OWS itself is a major supplier of the very products at issue, and at least three other competitors offer comparable silicon-photonics transceiver modules in the same speed and performance categories. There is no risk of product shortage or supply disruption as a result of an injunction against Lumicore's accused products. Hyperscale data-center operators have multiple qualified suppliers to choose from, and any temporary reduction in the number of available suppliers during Lumicore's redesign period would be more than offset by the capacity of existing suppliers, including OWS, to meet market demand.
C. Competition and Consumer Welfare
An injunction against Lumicore's accused products would not eliminate competition in the silicon-photonics transceiver market. OWS and at least three other suppliers serve the hyperscale data-center market, ensuring that customers have access to competitive product offerings and pricing. The market would continue to function effectively even during the period in which Lumicore undertakes a redesign of its products.
Moreover, Lumicore itself would remain free to compete in the market with non-infringing products after completing its redesign. A permanent injunction does not exclude Lumicore from the market permanently; it requires Lumicore to compete on the basis of its own innovations rather than on the basis of OWS's patented technologies. This is precisely the competitive dynamic that the patent system is designed to foster.
Consumers — in this case, hyperscale data-center operators — ultimately benefit from a patent system that encourages genuine innovation rather than copying. If competitors can freely appropriate the inventions of innovators like OWS, the pace and quality of innovation in the silicon-photonics market will decline, to the detriment of consumers. By contrast, enforcing OWS's patent rights through injunctive relief preserves the incentive structure that drives innovation, ultimately benefiting consumers through better products, improved performance, and greater technological advancement.
D. E.D. Tex. Precedent
Decisions from the Eastern District of Texas consistently support the conclusion that the public interest favors permanent injunctions in patent cases involving competing commercial products. Judge Gilstrap and other E.D. Tex. judges have found the public interest satisfied where the patentee is a practicing entity, the accused products are commercial (rather than essential or safety-critical) products, and alternative products are available in the market. See, e.g., Genband US LLC v. Metaswitch Networks Corp., No. 2:14-cv-33-JRG (E.D. Tex.) (Judge Gilstrap finding public interest favors injunction in competing commercial software case); Uniloc 2017 LLC v. Camberwell & Co., No. 2:18-cv-00069-JRG (E.D. Tex.) (discussing public-interest analysis in commercial-product context).
Importantly, none of the asserted patents in this case are standards-essential patents ("SEPs") subject to commitments to license on fair, reasonable, and non-discriminatory ("FRAND") terms. The public-interest analysis in cases involving SEPs is materially different from the analysis in non-SEP cases, because SEPs by definition are technologies that all market participants must use to comply with an industry standard, and the patentee has made a voluntary commitment to license on FRAND terms. Here, OWS's patents are proprietary technologies that Lumicore is free to design around. The public-interest considerations that counsel caution in SEP cases — concerns about hold-up, excessive royalties, and restraint of competition — are simply not implicated.
VIII. Potential Counterarguments and Responses
In anticipation of the arguments that Lumicore is likely to raise in opposition to OWS's request for a permanent injunction, we analyze each potential counterargument and set forth our recommended responses.
A. Lumicore Will Argue It Does Not Infringe (No Likelihood of Prevailing)
Anticipated Argument: Lumicore may argue that it does not infringe the asserted patents and that OWS cannot demonstrate the likelihood of prevailing on the merits necessary to support injunctive relief.
Response: This memorandum assumes a post-trial posture in which infringement has been established by the jury's verdict. At the permanent-injunction stage, the merits of infringement have alrea